Heska Announces Completion of Public Offering

Fort Collins, Colo. (PROTEXT) - Heska Corporation (Nasdaq:HSKA), today announced the completion of its previously announcedpublic offering of common stock. The Company sold 6,500,000shares of its common stock to several institutional investors,including the State of Wisconsin Investment Board, CharterVentures II, L.P. and Zesiger Capital Group LLC, all of whom wereexisting stockholders of Heska. The shares were sold at $2.063per share, the closing price of the Company's common stock on TheNasdaq Stock Market on November 30, 1999, the date the Company'sregistration statement relating to the shares was declaredeffective. Net proceeds from the offering totaled approximately$13.3 million. Heska Chief Executive Officer, Robert Grieve, said, "We areextremely pleased that there was strong demand for this offeringand that some of our largest institutional shareholders haveincreased their equity position in the Company. For the pastyear, we have been focused on improving our operating results,while also developing a diverse product pipeline to support ourlong-term growth. We believe that this investment reflects anappreciation of the significant progress we are making in theseareas. This financing is a part of our strategy for strengtheningthe Company's financial position and providing the funds neededto sustain our continued growth." John Nelson, Investment Director for the State of WisconsinInvestment Board said, "This investment will assist Heska'slaunch of new products into markets which we believe havesignificant potential. We continue to be impressed with theresearch progress achieved by the Company and their ability tointroduce innovative products." The State of Wisconsin Investment Board manages investments ofover $60 billion on behalf of 455,000 government employees andretirees. Heska discovers, develops, manufactures and markets companionanimal health products, primarily for dogs, cats and horses.Heska has a sophisticated scientific effort devoted to applyingbiotechnology to create a broad range of diagnostic, therapeuticand vaccine products for the large and growing companion animalhealth market. In addition to its diagnostic, therapeutic andvaccine products, Heska also offers patient monitoringinstrumentation and supplies, as well as laboratory diagnosticproducts and services in the United States and Europe toveterinarians, and operates USDA- and FDA-licensed facilities,which manufacture certain of our products. ots Original TextService: Heska Corporation Internet: http://www.newsaktuell.deContact: Ron Hendrick, Executive Vice President & CFO, or RobertGrieve, Chief Executive Officer, of Heska Corporation, (USA) 970-493-7272 Web site: http://www.heska.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT